SLT not best for PEXG patients

Article

Performing selective laser trabeculoplasty (SLT) in patients with pseudoexfoliative glaucoma (PEXG) may in fact cause a rise in intraocular pressure (IOP), according to results published in the October issue of BMC Ophthalmology.

Performing selective laser trabeculoplasty (SLT) in patients with pseudoexfoliative glaucoma (PEXG) may in fact cause a rise in intraocular pressure (IOP), according to results published in the October issue of BMC Ophthalmology.

Mauro Cellini of the Department of Surgery Science and Anaesthesiology, Ophthalmology Service, University of Bologna, Italy and colleagues evaluated changes in metalloproteinases (MMP-2) and tissue inhibitor of metalloproteinases (TIMP-2) in PEXG patients by assessing the concentrations in the aqueous humour of MMP-2 and TIMP-2 after phacoemulsification in PEXG with cataract patients (n=15) and after SLT in PEXG patients (n=15), and compared these levels with those of the control group (n=15).

Before SLT treatment, patients had a mean IOP of 25.8±1.9 mmHg. Following SLT treatment, IOP initially dropped but then rebounded to pre-treatment levels, necessitating trabeculectomy: at day 10, IOP was 18.1±1.4 mmHg; at 31.5±7.6 days, IOP was 25.4±1.6 mmHg. In these patients, MMP-2 and TIMP-2 were 58.52±9.66 µg/ml and 105.96±27.65 µg/ml, respectively. In PEXG with cataract patients, these levels were 57.77±9.25 µg/ml and 105.19±28.53 µg/ml, respectively. The ratio of MMP-2 to TIMP-2 was 1.87:0.64 in the PEXG group, 1.88:0.65 in the PEXG with cataract group and 1.11:0.44 in control subjects.

The researchers concluded that this increase in the MMP-2/TIMP-2 ratio may be associated with any IOP increase that occurs after SLT in PEXG patients.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.